Biotech: Page 13

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

    President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

    By BioPharma Dive staff • March 14, 2025
  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

    The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

    By • March 13, 2025
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche broadens obesity drug plans with $1.65B Zealand deal

    The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

    By • March 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

    Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.

    By BioPharma Dive staff • March 12, 2025
  • A group of scientists and executives with Lila Sciences.
    Image attribution tooltip
    Permission granted by Lila Sciences
    Image attribution tooltip

    Flagship startup raises $200M in pursuit of ‘scientific superintelligence’

    Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up the experimentation process.

    By • March 12, 2025
  • An illustration of red and white blood cells clustered against a pink background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ono pays $280M to license Ionis rare disease drug

    Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

    By Kristin Jensen • March 12, 2025
  • CordenPharma’s Integrated Supply from peptide drug substance to injectable and oral solid dosage manufacturing.
    Image attribution tooltip
    Courtesy of CordenPharma
    Image attribution tooltip

    Viking inks CordenPharma deal to boost obesity drug supply

    The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

    By • March 11, 2025
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Arvinas gets positive breast cancer data, but finds differentiation a hard sell

    Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.

    By Ned Pagliarulo • March 11, 2025
  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam base editing therapy gets ‘proof of concept’ in rare lung disease

    While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.

    By Ned Pagliarulo • March 10, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche launches new Boston center; NIH centralizes peer review

    The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio, Bayer’s gene therapy subsidiary, advanced an experimental treatment for limb-girdle muscular dystrophy. 

    By BioPharma Dive staff • March 7, 2025
  • Portrait of Jeb Keiper, CEO of Nimbus Therapeutics.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics
    Image attribution tooltip

    Nimbus swaps CEOs and turns to new leader for ‘next chapter’

    CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug startup.

    By • March 7, 2025
  • A bottle of Vertex Pharmaceuticals' new pain medicine Journavx.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip
    Pain drugs

    Vertex’s new pain drug gets first coverage nod from major insurer

    Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an interim decision while a formal review continues.

    By • March 6, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Federal judge extends block on Trump plan to limit NIH payouts

    A District Court judge issued a nationwide preliminary injunction against the administration’s plan to cap so-called indirect costs associated with NIH grants — a policy with broad implications for the U.S. drug industry.  

    By Kristin Jensen • March 6, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

    Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for testing a first-of-its-kind base editing therapy for Duchenne.

    By BioPharma Dive staff • March 6, 2025
  • A person writes on a check.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sofinnova secures €1.2B for new biotech investments

    The funding can support investment in as many as 60 new life sciences companies, said Sofinnova chairman Antoine Papiernik.

    By • March 4, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

    Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

    By BioPharma Dive staff • March 4, 2025
  • An illustration of leukocytes attacking a cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive // State of Play

    Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

    Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.

    By • March 4, 2025
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

    Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

    By • March 3, 2025
  • An illustration of the KRAS protein
    Image attribution tooltip
    Retrieved from National Cancer Institute on September 27, 2019
    Image attribution tooltip

    BridgeBio oncology spinout to go public in blank-check merger

    The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.

    By • Feb. 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

    The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

    By BioPharma Dive staff • Feb. 28, 2025
  • A sign spelling Vertex hangs over an office building entrance.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip
    Gene editing

    Vertex ends gene editing research pact with Verve

    Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.”

    By Kristin Jensen • Feb. 27, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

    The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

    By BioPharma Dive staff • Feb. 26, 2025
  • A visualization, in green lights, of Eikon's particle tracking platform.
    Image attribution tooltip
    Permission granted by Eikon Therapeutics
    Image attribution tooltip
    Startup launches

    Eikon raises $351M in one of the year’s largest biotech venture rounds

    The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs.

    By • Feb. 26, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts

    The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, investors said.

    By • Feb. 25, 2025
  • artwork symbolizing biotechnology and clinical trials
    Image attribution tooltip
    Permission granted by ICON
    Image attribution tooltip
    Sponsored by ICON

    Partnering for success in early phase clinical development

    Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

    Feb. 24, 2025